ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

FTC Seeks Additional Info From Teva, Cephalon Regarding Merger

DOW JONES NEWSWIRES Teva Pharmaceutical Industries Ltd. (TEVA, TEVA.TV) and acquisition target Cephalon Inc. (CEPH) each received a request to provide additional information to the U.S. Federal Trade Commission related to a pending $6.8 billion deal between the firms. Israel-based Teva, which trumped a hostile offer from Valeant Pharmaceuticals International Inc. (VRX) in agreeing to buy Cephalon last month, said it had expected the request. The parties have been cooperating with the FTC staff since shortly after the bid was announced, according to Teva, which said it intends to win clearance "as promptly as possible." Teva on Monday said it continues to expect the deal to be completed in the third quarter, following clearance from U.S. and European regulators, as well as winning approval of Cephalon shareholders. Teva's American depositary shares were recently up 0.4% to $49.35 in after-hours trading. -By John Kell, Dow Jones Newswires; 212-416-2480; john.kell@dowjones.com

Stock News for Valeant Pharma (VRX)
DateTimeHeadline
05/25/201501:00:00Pharming and Cytobioteck Announce Distribution Agreement for...
05/23/201512:03:02Billionaire George Soros Just Sold These 3 Stocks: Should You?
05/21/201516:48:48Initial Statement of Beneficial Ownership (3)
05/19/201517:00:00Valeant Pharmaceuticals Announces 2015 Annual Meeting Results
05/19/201517:00:00Valeant Pharmaceuticals Announces 2015 Annual Meeting Results
05/19/201516:59:40Current Report Filing (8-k)
05/18/201512:18:57Endo to Buy Generics Maker Par Pharma for $8 Billion -- 4th Update
05/18/201511:05:26Endo to Buy Generics Maker Par Pharma for $8 Billion -- 3rd Update
05/18/201501:00:00Pharming and Clinigen Group Initiate "HAEi GAP" Global Access...
05/15/201522:41:08
05/15/201519:55:34Third Point Sells Entire $1 Billion Stake in Alibaba
05/15/201519:42:17Hedge Fund Dumps Alibaba
05/12/201516:05:00Valeant Pharmaceuticals To Webcast 2015 Annual Meeting Of Shareholders
05/12/201516:05:00Valeant Pharmaceuticals To Webcast 2015 Annual Meeting Of Shareholders
05/10/201514:18:02Meet the Company That May Become Healthcare's Version of Berkshire...
05/10/201513:03:02Investors Just Doubled Their Money on This Stock
05/06/201517:53:12Statement of Changes in Beneficial Ownership (4)
05/05/201516:58:55Statement of Changes in Beneficial Ownership (4)
05/04/201519:26:00From Einhorn to Ackman, Live From the Ira Sohn Conference...
04/30/201515:43:06Quarterly Report (10-q)

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad